Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis

The Lancet Infectious Diseases

Volumn 10, Issue 7, 2010, Pages 464-469

  Werb, Daniel ^a   Mills, Edward J ^a   Montaner, Julio SG ^a   Wood, Evan ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; COMPARATIVE STUDY; DRUG ABUSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VIROLOGY;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; DRUG RESISTANCE, VIRAL; EUROPE; HIV SEROPOSITIVITY; HUMANS; MIDDLE AGED; NORTH AMERICA; PATIENT SELECTION; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 77953631014     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70097-9     Document Type: Review

References (44)

1. Mathers B.M., Degenhardt L., Phillips B., et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372 (2008) 1733-1745
2. Wolfe D., and Malinowska-Sempruch K. Illicit drug policies and the global HIV epidemic: effects of UN and national government approaches (2004), Open Society Institute, New York
3. Hogg R., Cahn P., Katabira E.T., et al. Time to act: global apathy towards HIV/AIDS is a crime against humanity. The Lancet 360 (2002) 1710-1711
4. Wood E., Kerr T., Tyndall M.W., and Montaner J.S. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 22 (2008) 1247-1256
5. Jha C.K., and Madison J. Disparity in health care: HIV, stigma, and marginalization in Nepal. J Int AIDS Soc 12 (2009) 16
6. Ding L., Landon B.E., Wilson I.B., Wong M.D., Shapiro M.F., and Cleary P.D. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med 165 (2005) 618-623
7. Vervoort S.C.J.M., Borleffs J.C.C., Hoepelman A., and Grypdonck M.H.F. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS 21 (2007) 271-281
8. Mills E.J., Nachega J.B., Bangsberg D.R., et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 3 (2006) e438
9. Malta M., Strathdee S., Magnanini M.M.F., and Bastos F.I. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 103 (2008) 1242-1257
10. Bennett D.E., Camacho R.J., Otelea D., et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4 (2009) e4724
11. Wainberg M.A., and Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279 (1998) 1977-1983
12. Wood E., Hogg R.S., Heath K.V., et al. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. AIDS 17 (2003) 2629-2634
13. Carrieri M.P., Chesney M.A., Spire B., et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med 10 (2003) 1-14
14. Bassetti S., Battegay M., Furrer H., et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 21 (1999) 114-119
15. Hogg R.S., Heath K., Bangsberg D., et al. Intermittent use of triple combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16 (2002) 1051-1058
16. Wood E., Hogg R.S., Bonner S., et al. Staging for antiretroviral therapy among HIV-infected drug users. JAMA 292 (2004) 1175-1177
17. Egger M., Smith G.D., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
18. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
19. Wells G.A., Shea B., O'Connell D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews: Beyond the Basics. Oxford, UK (July 3-5, 2000). http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed July 8, 2008).
20. Rücker G., Schwarzer G., Carpenter J.R., and Schumacher M. Undue reliance on I2 in assessing heterogeneity may mislead. BMC Med Res Methodol 8 (2008) 79
21. Higgins J.P.T., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
22. Borenstein M., Hedges L.V., Higgins J.P.T., and Rothstein H.R. Introduction to meta-analysis (statistics in practice) (2009), Wiley-Blackwell, Chichester
23. Gomez-Cano M., Rubio A., Puig T., et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 12 (1998) 1015-1020
24. Salomon H., Wainberg M.A., Brenner B., et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14 (2000) F17-F23
25. Yerly S., Vora S., Rizzardi P., et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 15 (2001) 2287-2292
26. Horban A., Stanczak J.J., Bakowska E., et al. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort. Infection 30 (2002) 356-359
27. Bezemer D., Jurriaans S., Prins M., et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 18 (2004) 1571-1577
28. Weinstock H.S., Zaidi I., Heneine W., et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189 (2004) 2174-2180
29. Moore R.D., Keruly J.C., and Chaisson R.E. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 35 (2004) 46-51
30. Richman D.D., Morton S.C., Wrin T., et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
31. Wood E., Hogg R., Yip B., et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 19 (2005) 1189-1195
32. Cane P., Chrystie I., Dunn D., et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331 (2005) 1368
33. Paraskevis D., Magiorkinis E., Katsoulidou A., et al. Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res 112 (2005) 115-122
34. Masquelier B., PharmD P.D., Bhaskaran K., et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE Collaboration From 1987 to 2003. J Acquir Immune Defic Syndr 40 (2005) 505-511
35. Yerly S., von Wyl V., Ledergerber B., et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21 (2007) 2223-2229
36. Chang S.-Y., Chen M.-Y., Lee C.-N., et al. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother 61 (2008) 689-693
37. WHO. WHO, HIV/AIDS treatment and care for injecting drug users: Clinical protocol for the WHO European region (2006), World Health Organization Regional Office for Europe, Copenhagen
38. Malta M., Magnanini M.M., Strathdee S.A., and Bastos F.I. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav (2008) 10.1007/s10461-008-9489-7 published online Nov 20.
39. Spire B., Lucas G.M., and Carrieri M.P. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Pol 18 (2007) 262-270
40. Waldrop-Valverde D. Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care STDS 19 (2005) 326-334
41. Tucker J.S., Burnam M.A., Sherbourne C.D., Kung F.-Y., and Gifford A. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 114 (2003) 573-580
42. Harrigan B.P., Hogg R., Dong W.Y., et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191 (2005) 339-347
43. Bangsberg D., Moss A., and Deek S.G. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 53 (2004) 696-699
44. Ioannidis J.P., Patsopoulos N.A., and Rothstein H.R. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ 336 (2008) 1413-1415